

Ãgatha Oliveira-Giacomelli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6542916/publications.pdf>

Version: 2024-02-01

33
papers

1,189
citations

361045
20
h-index

433756
31
g-index

33
all docs

33
docs citations

33
times ranked

1730
citing authors

#	ARTICLE	IF	CITATIONS
1	Antidepressant-like effects of fractions, essential oil, carnosol and betulinic acid isolated from <i>Rosmarinus officinalis</i> L.. <i>Food Chemistry</i> , 2013, 136, 999-1005.	4.2	113
2	Creatine, Similar to Ketamine, Counteracts Depressive-Like Behavior Induced by Corticosterone via PI3K/Akt/mTOR Pathway. <i>Molecular Neurobiology</i> , 2016, 53, 6818-6834.	1.9	111
3	Hyperactivation of P2X7 receptors as a culprit of COVID-19 neuropathology. <i>Molecular Psychiatry</i> , 2021, 26, 1044-1059.	4.1	104
4	The P2X7 Receptor: Central Hub of Brain Diseases. <i>Frontiers in Molecular Neuroscience</i> , 2020, 13, 124.	1.4	87
5	Guanosine produces an antidepressant-like effect through the modulation of NMDA receptors, nitric oxideâ€cGMP and PI3K/mTOR pathways. <i>Behavioural Brain Research</i> , 2012, 234, 137-148.	1.2	77
6	Purinergic receptors in embryonic and adult neurogenesis. <i>Neuropharmacology</i> , 2016, 104, 272-281.	2.0	74
7	Involvement of PI3K/Akt Signaling Pathway and Its Downstream Intracellular Targets in the Antidepressant-Like Effect of Creatine. <i>Molecular Neurobiology</i> , 2016, 53, 2954-2968.	1.9	50
8	Serotonergic and noradrenergic systems are implicated in the antidepressant-like effect of ursolic acid in mice. <i>Pharmacology Biochemistry and Behavior</i> , 2014, 124, 108-116.	1.3	43
9	Purinergic Receptors in Neurological Diseases With Motor Symptoms: Targets for Therapy. <i>Frontiers in Pharmacology</i> , 2018, 9, 325.	1.6	42
10	The modulation of NMDA receptors and l-arginine/nitric oxide pathway is implicated in the anti-immobility effect of creatine in the tail suspension test. <i>Amino Acids</i> , 2015, 47, 795-811.	1.2	40
11	Brilliant Blue G, but not Fenofibrate, Treatment Reverts Hemiparkinsonian Behavior and Restores Dopamine Levels in an Animal Model of Parkinson's Disease. <i>Cell Transplantation</i> , 2017, 26, 669-677.	1.2	39
12	P2Y6 and P2X7 Receptor Antagonism Exerts Neuroprotective/ Neuroregenerative Effects in an Animal Model of Parkinson's Disease. <i>Frontiers in Cellular Neuroscience</i> , 2019, 13, 476.	1.8	38
13	The Antidepressant-like Effect of Physical Activity on a Voluntary Running Wheel. <i>Medicine and Science in Sports and Exercise</i> , 2013, 45, 851-859.	0.2	35
14	Creatine, similarly to ketamine, affords antidepressant-like effects in the tail suspension test via adenosine A1 and A2A receptor activation. <i>Purinergic Signalling</i> , 2015, 11, 215-227.	1.1	34
15	The activation of β -1-adrenoceptors is implicated in the antidepressant-like effect of creatine in the tail suspension test. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013, 44, 39-50.	2.5	32
16	MPP+-Lesioned Mice: an Experimental Model of Motor, Emotional, Memory/Learning, and Striatal Neurochemical Dysfunctions. <i>Molecular Neurobiology</i> , 2017, 54, 6356-6377.	1.9	31
17	Evidence for the involvement of 5-HT1A receptor in the acute antidepressant-like effect of creatine in mice. <i>Brain Research Bulletin</i> , 2013, 95, 61-69.	1.4	29
18	Involvement of PKA, PKC, CAMK-II and MEK1/2 in the acute antidepressant-like effect of creatine in mice. <i>Pharmacological Reports</i> , 2014, 66, 653-659.	1.5	24

#	ARTICLE	IF	CITATIONS
19	Pathophysiology in the comorbidity of Bipolar Disorder and Alzheimer's Disease: pharmacological and stem cell approaches. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 80, 34-53.	2.5	24
20	Purinergic Receptors in Basal Ganglia Diseases: Shared Molecular Mechanisms between Huntingtonâ€™s and Parkinsonâ€™s Disease. <i>Neuroscience Bulletin</i> , 2020, 36, 1299-1314.	1.5	24
21	ATP and spontaneous calcium oscillations control neural stem cell fate determination in Huntingtonâ€™s disease: a novel approach for cell clock research. <i>Molecular Psychiatry</i> , 2021, 26, 2633-2650.	4.1	24
22	Role of P2X7 Receptors in Immune Responses During Neurodegeneration. <i>Frontiers in Cellular Neuroscience</i> , 2021, 15, 662935.	1.8	24
23	Purinergic receptors in neurogenic processes. <i>Brain Research Bulletin</i> , 2019, 151, 3-11.	1.4	22
24	Midbrain Dopaminergic Neurons Differentiated from Human-Induced Pluripotent Stem Cells. <i>Methods in Molecular Biology</i> , 2019, 1919, 97-118.	0.4	18
25	Effects of Magnetite Nanoparticles and Static Magnetic Field on Neural Differentiation of Pluripotent Stem Cells. <i>Stem Cell Reviews and Reports</i> , 2022, 18, 1337-1354.	1.7	18
26	Intracellular Calcium Measurements for Functional Characterization of Neuronal Phenotypes. <i>Methods in Molecular Biology</i> , 2015, 1341, 245-255.	0.4	8
27	Targeting Purinergic Signaling and Cell Therapy in Cardiovascular and Neurodegenerative Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1201, 275-353.	0.8	8
28	Mesenchymal stem cellâ€“glioblastoma interactions mediated via kinin receptors unveiled by cytometry. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2021, 99, 152-163.	1.1	6
29	Antagonistic Roles of P2X7 and P2Y2 Receptors in Neurodegenerative Diseases. <i>Frontiers in Pharmacology</i> , 2021, 12, 659097.	1.6	4
30	Brilliant Blue-G but not Fenofibrate Treatment Reverts Hemiparkinsonian Behavior and Restores Dopamine Levels in an Animal Model of Parkinsonâ€™s Disease. <i>Cell Transplantation</i> , 2017, , .	1.2	3
31	Stem Cells: Principles and Applications. , 2016, , 1-13.		1
32	Dopaminergic and GABAergic Neuron In Vitro Differentiation from Embryonic Stem Cells. <i>Neuromethods</i> , 2017, , 45-53.	0.2	1
33	Restoring dopamine levels in Parkinson's disease: neuronal pathways, agonists and antiinflammatory agents. , 2020, , 479-493.		1